In vitro interaction between alginate lyase and amphotericin B against aspergillus fumigatus biofilm determined by different methods

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 3, 2013, Pages 1275-1282

  Bugli, Francesca ^a   Posteraro, Brunella ^a   Papi, Massimiliano ^a   Torelli, Riccardo ^a   Maiorana, Alessandro ^a   Sterbini, Francesco Paroni ^a   Posteraro, Patrizia ^b   Sanguinetti, Maurizio ^a   De Spirito, Marco ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b Ospedale San Carlo   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; AMPHOTERICIN B; POLYENE ANTIBIOTIC AGENT;

ARTICLE; ASPERGILLUS FUMIGATUS; ATOMIC FORCE MICROSCOPY; BIOFILM; CONTROLLED STUDY; DRUG FORMULATION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; BACTERIAL PROTEINS; BIOFILMS; DEOXYCHOLIC ACID; DRUG COMBINATIONS; DRUG SYNERGISM; FUNGAL POLYSACCHARIDES; HYPHAE; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ATOMIC FORCE; POLYSACCHARIDE-LYASES;

EID: 84874036782     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01875-12     Document Type: Article

References (44)

1. O'Toole G, Kaplan HB, Kolter R. 2000. Biofilm formation as microbial development. Annu. Rev. Microbiol. 54:49 -79.
2. Dagenais TR, Keller NP. 2009. Pathogenesis of Aspergillus fumigatus in invasive aspergillosis. Clin. Microbiol. Rev. 22:447- 465.
3. Ramage G, Rajendran R, Gutierrez-Correa M, Jones B, Williams C. 2011. Aspergillus biofilms: clinical and industrial significance. FEMS Microbiol. Lett. 324:89 -97.
4. Beauvais A, Schmidt C, Guadagnini S, Roux P, Perret E, Henry C, Paris S, Mallet A, Prévost MC, Latgé JP. 2007. An extracellular matrix glues together the aerial-grown hyphae of Aspergillus fumigatus. Cell. Microbiol. 9:1588 -1600.
5. Loussert C, Schmitt C, Prevost MC, Balloy V, Fadel E, Philippe B, Kauffmann-Lacroix C, Latgé JP, Beauvais A. 2010. In vivo biofilm composition of Aspergillus fumigatus. Cell. Microbiol. 12:405- 410.
6. Mowat E, Butcher J, Lang S, Williams C, Ramage G. 2007. Development of a simple model for studying the effects of antifungal agents on multicellular communities of Aspergillus fumigatus. J. Med. Microbiol. 56: 1205-1212.
7. Müller FM, Seidler M, Beauvais A. 2011. Aspergillus fumigatus biofilms in the clinical setting. Med. Mycol. 49(Suppl 1):S96 -S100.
8. Ramage G, Mowat E, Jones B, Williams C, Lopez-Ribot J. 2009. Our current understanding of fungal biofilms. Crit. Rev. Microbiol. 35: 340 -355.
9. Seidler MJ, Salvenmoser S, Müller FM. 2008. Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells. Antimicrob. Agents Chemother. 52:4130-4136.
10. Donlan RM, Costerton JW. 2002. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin. Microbiol. Rev. 15:167-193.
11. Hall-Stoodley L, Costerton JW, Stoodley P. 2004. Bacterial biofilms: from the natural environment to infectious diseases. Nat. Rev. Microbiol. 2:95-108.
12. Fiori B, Posteraro B, Torelli R, Tumbarello M, Perlin DS, Fadda G, Sanguinetti M. 2011. In vitro activities of anidulafungin and other antifungal agents against biofilms formed by clinical isolates of different Candida and Aspergillus species. Antimicrob. Agents Chemother. 55:3031- 3035.
13. Mowat E, Lang S, Williams C, McCulloch E, Jones B, Ramage G. 2008. Phase-dependent antifungal activity against Aspergillus fumigatus developing multicellular filamentous biofilms. J. Antimicrob. Chemother. 62: 1281-1284.
14. Ramage G, Rajendran R, Sherry L, Williams C. 2012. Fungal biofilm resistance. Int. J. Microbiol. 2012:528521. doi:10.1155/2012/528521.
15. Segal BH, Almyroudis NG, Battiwalla M, Herbrecht R, Perfect JR, Walsh TJ, Wingard JR. 2007. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin. Infect. Dis. 44:402- 409.
16. Moen MD, Lyseng-Williamson KA, Scott LJ. 2009. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs 69:361-392.
17. Traunmüller F, Popovic M, Konz KH, Smolle-Jüttner FM, Joukhadar C. 2011. Efficacy and safety of current drug therapies for invasive aspergillosis. Pharmacology 88:213-224.
18. van de Sande WW, Tavakol M, van Vianen W, Bakker-Woudenberg IA. 2010. The effects of antifungal agents to conidial and hyphal forms of Aspergillus fumigatus. Med. Mycol. 48:48 -55.
19. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. 2002. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother. 46:1773-1780.
20. Seidler MJ, Salvenmoser S, Müller FM. 2010. Liposomal amphotericin B eradicates Candida albicans biofilm in a continuous catheter flow model. FEMS Yeast Res. 10:492- 495.
21. Alipour M, Suntres ZE, Omri A. 2009. Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa. J. Antimicrob. Chemother. 64:317-325.
22. Brackman G, Cos P, Maes L, Nelis HJ, Coenye T. 2011. Quorum sensing inhibitors increase the susceptibility of bacterial biofilms to antibiotics in vitro and in vivo. Antimicrob. Agents Chemother. 55:2655-2661.
23. Laniado-Laborín R, Cabrales-Vargas MN. 2009. Amphotericin B: side effects and toxicity. Rev. Iberoam. Micol. 26:223-227.
24. Wong TY, Preston LA, Schiller NL. 2000. Alginate lyase: review of major sources and enzyme characteristics, structure-function analysis, biological roles, and applications. Annu. Rev. Microbiol. 54:289 -340.
25. Alkawash MA, Soothill JS, Schiller NL. 2006. Alginate lyase enhances antibiotic killing of mucoid Pseudomonas aeruginosa in biofilms. APMIS 114:131-138.
26. Konno N, Ishida T, Igarashi K, Fushinobu S, Habu N, Samejima M, Isogai A. 2009. Crystal structure of polysaccharide lyase family 20 endobeta- 1, 4-glucuronan lyase from the filamentous fungus Trichoderma reesei. FEBS Lett. 583:1323-1326.
27. Wright CJ, Shah MK, Powell LC, Armstrong I. 2010. Application of AFM from microbial cell to biofilm. Scanning 32:134 -149.
28. Pierce CG, Uppuluri P, Tristan AR, Wormley FL Jr, Mowat E, Ramage G, Lopez-Ribot JL. 2008. A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nat. Protoc. 3:1494 -1500.
29. Colozza C, Posteraro B, Santilli S, De Carolis E, Sanguinetti M, Girmenia C. 2012. In vitro activities of amphotericin B and AmBisome against Aspergillus isolates recovered from Italian patients treated for haematological malignancies. Int. J. Antimicrob. Agents 39:440-443.
30. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard, 2nd ed. M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
31. Meletiadis J, Mouton JW, Meis JF, Bouman BA, Donnelly JP, Verweij PE. 2001. Colorimetric assay for antifungal susceptibility testing of Aspergillus species. J. Clin. Microbiol. 39:3402-3408.
32. Meletiadis J, Mouton JW, Meis JF, Verweij PE. 2003. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob. Agents Chemother. 47:106 -117.
33. Meletiadis J, Pournaras S, Roilides E, Walsh TJ. 2010. Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus. Antimicrob. Agents Chemother. 54:602- 609.
34. Papi M, Maiorana A, Bugli F, Torelli R, Posteraro B, Maulucci G, De Spirito M, Sanguinetti M. 2012. Detection of biofilm-grown Aspergillus fumigatus by means of atomic force spectroscopy: ultrastructural effects of alginate lyase. Microsc. Microanal. 18:1088 -1094.
35. Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. 2004. Combination antifungal therapy. Antimicrob. Agents Chemother. 48:693-715.
36. Odds FC. 2003. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52:1.
37. Zhou Y, Wang G, Li Y, Liu Y, Song Y, Zheng W, Zhang N, Hu X, Yan S, Jia J. 2012. In vitro interactions between aspirin and amphotericin B against planktonic cells and biofilm cells of Candida albicans and C. parapsilosis. Antimicrob. Agents Chemother. 56:3250 -3260.
38. Demchok JP, Meletiadis J, Roilides E, Walsh TJ. 2010. Comparative pharmacodynamic interaction analysis of triple combinations of caspofungin and voriconazole or ravuconazole with subinhibitory concentrations of amphotericin B against Aspergillus spp. Mycoses 53:239 -245.
39. O'Shaughnessy EM, Meletiadis J, Stergiopoulou T, Demchok JP, Walsh TJ. 2006. Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species. J. Antimicrob. Chemother. 58:1168 -1176.
40. Afeltra J, Vitale RG, Mouton JW, Verweij PE. 2004. Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds and itraconazole against clinical isolates of Aspergillus fumigatus resistant to itraconazole. Antimicrob. Agents Chemother. 48:1335-1343.
41. Vediyappan G, Rossignol T, d'Enfert C. 2010. Interaction of Candida albicans biofilms with antifungals: transcriptional response and binding of antifungals to beta-glucans. Antimicrob. Agents Chemother. 54:2096- 2111.
42. Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. 2002. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob. Agents Chemother. 46:828-833.
43. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF, Infectious Diseases Society of America. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360.
44. Steinbach WJ, Juvvadi PR, Fortwendel JR, Rogg LE. 2011. Newer combination antifungal therapies for invasive aspergillosis. Med. Mycol. 49(Suppl 1):S77-S81.